[Hemolytic uremic syndrome after bone marrow transplantation]

Area of Science:

• Hematology
• Nephrology
• Oncology

Context:

• Bone marrow transplantation (BMT) is a critical treatment for various hematologic malignancies and other diseases.
• Hemolytic uremic syndrome (HUS) is a serious complication that can arise post-transplantation.
• Understanding the incidence and risk factors of HUS after BMT is crucial for patient management.

Purpose:

• To investigate the incidence of hemolytic uremic syndrome (HUS) in patients following autologous or allogeneic bone marrow transplantation (BMT).
• To identify potential risk factors associated with the development of HUS post-BMT.
• To describe the clinical course and management of HUS in this patient cohort.

Summary:

• Seven out of 113 patients developed HUS between 36-196 days post-BMT.
• Patients with acute lymphocytic leukemia (ALL) and those preconditioned with fractionated total body irradiation (TBI) were suspected risk factors.
• Treatment involved discontinuing Cyclosporin A (CSP), administering Prednisolone, and in one case, plasma exchange, with variable outcomes for renal function.

Impact:

• This study highlights the risk of HUS following BMT, particularly in patients with ALL undergoing TBI-based conditioning.
• Findings can inform risk stratification and monitoring protocols for BMT recipients.
• Early recognition and management strategies for HUS post-BMT may improve patient outcomes.